Mymetics Corporation (MYMX)

Market Cap	46.00 -100.0%
Revenue (ttm)	564.14K -44.7%
Net Income	-12.24M
EPS	-80.61
Shares Out	151.88K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	143
Average Volume	387
Open	0.0003
Previous Close	0.0003
Day's Range	0.0003 - 0.0003
52-Week Range	0.0003 - 0.0003
Beta	2.33
RSI	37.20
Earnings Date	n/a

About Mymetics

Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company’s product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, and malaria. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; and national institutes of health. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corpora...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: MYMX

Financial Performance

In 2022, Mymetics's revenue was 1.03 million, an increase of 139.07% compared to the previous year's 430,000. Losses were -4.81 million, 1.59% more than in 2021.

Financial numbers in EUR